Chemical: Drug
thioridazine

PharmGKB contains no dosing guidelines for this . To report known genotype-based dosing guidelines, or if you are interested in developing guidelines, click here.


last updated 10/25/2013

1. FDA Label for thioridazine and CYP2D6

Actionable PGx

Summary

Thioridazine is used to treat schizophrenia, but has been associated with Torsades de pointes and sudden death. Due to the potentially fatal side effects, it is typically reserved for patients who do not respond well to other anti-psychotics. This drug is contraindicated in patients with reduced CYP2D6 activity.

Annotation

Thioridazine is used to treat schizophrenic patients. It has potentially fatal effects on heart rhythm and should only be used if other antipsychotic drugs are not effective or cause intolerable side effects. Its use is warned against in people with reduced CYP2D6 activity and hence, reduced clearance of the drug, as that increases the likelihood of the potential fatal effects.

Excerpts from the thioridazine drug label:

Therefore, thioridazine is contraindicated with these drugs as well as in patients, comprising about 7% of the normal population, who are known to have a genetic defect leading to reduced levels of activity of P450 2D6.

Certain circumstances may increase the risk of Torsades de pointes and/or sudden death in association with the use of drugs that prolong the QTc interval, including 1) bradycardia, 2) hypokalemia, 3) concomitant use of other drugs that prolong the QTc interval, 4) presence of congenital prolongation of the QT interval, and 5) for thioridazine in particular, its use in patients with reduced activity of P450 2D6 or its coadministration with drugs that may inhibit P450 2D6 or by some other mechanism interfere with the clearance of thioridazine.

For the complete drug label text with sections containing pharmacogenetic information highlighted, see the Thioridazine drug label.

*Disclaimer: The contents of this page have not been endorsed by the FDA and are the sole responsibility of PharmGKB.

Full label available at DailyMed

Genes and/or phenotypes found in this label

  • congenital long QT syndrome
    • Contraindications section
    • source: PHONT
  • Death, Sudden, Cardiac
    • Contraindications section, Warnings section, Adverse reactions section, Precautions section
    • source: PHONT
  • Long QT Syndrome
    • Contraindications section
    • source: PHONT
  • Schizophrenia
    • Indications & usage section
    • source: U.S. Food and Drug Administration
  • Torsades de Pointes
    • Contraindications section, Warnings section, Adverse reactions section, Precautions section
    • source: PHONT
  • CYP2D6
    • metabolism/PK, Contraindications section, Warnings section, Precautions section
    • source: U.S. Food and Drug Administration

PharmGKB contains no Clinical Variants that meet the highest level of criteria.

To see more Clinical Variants with lower levels of criteria, click the button at the bottom of the page.

Disclaimer: The PharmGKB's clinical annotations reflect expert consensus based on clinical evidence and peer-reviewed literature available at the time they are written and are intended only to assist clinicians in decision-making and to identify questions for further research. New evidence may have emerged since the time an annotation was submitted to the PharmGKB. The annotations are limited in scope and are not applicable to interventions or diseases that are not specifically identified.

The annotations do not account for individual variations among patients, and cannot be considered inclusive of all proper methods of care or exclusive of other treatments. It remains the responsibility of the health-care provider to determine the best course of treatment for a patient. Adherence to any guideline is voluntary, with the ultimate determination regarding its application to be made solely by the clinician and the patient. PharmGKB assumes no responsibility for any injury or damage to persons or property arising out of or related to any use of the PharmGKB clinical annotations, or for any errors or omissions.

? = Mouse-over for quick help

The table below contains information about pharmacogenomic variants on PharmGKB. Please follow the link in the "Variant" column for more information about a particular variant. Each link in the "Variant" column leads to the corresponding PharmGKB Variant Page. The Variant Page contains summary data, including PharmGKB manually curated information about variant-drug pairs based on individual PubMed publications. The PMIDs for these PubMed publications can be found on the Variant Page.

The tags in the first column of the table indicate what type of information can be found on the corresponding Variant Page.

Links in the "Gene" column lead to PharmGKB Gene Pages.

List of all variant annotations for thioridazine

Gene ? Variant?
(147)
Alternate Names ? Chemicals ? Alleles ?
(+ chr strand)
Function ? Amino Acid?
Translation
VIP No VIP available No VIP available CYP2D6 *1 N/A N/A N/A
VIP No VIP available No VIP available CYP2D6 *2 N/A N/A N/A
VIP No VIP available No VIP available CYP2D6 *3 N/A N/A N/A
VIP No VIP available No VIP available CYP2D6 *4 N/A N/A N/A
VIP No VIP available No VIP available CYP2D6 *6 N/A N/A N/A
VIP No VIP available No VIP available CYP2D6 *9 N/A N/A N/A
VIP No VIP available No VIP available CYP2D6 *10 N/A N/A N/A
VIP No VIP available No VIP available CYP2D6 *17 N/A N/A N/A
VIP No VIP available No VIP available CYP2D6 *29 N/A N/A N/A
VIP No VIP available No VIP available CYP2D6 *41 N/A N/A N/A
VIP No Clinical Annotations available No Variant Annotations available
rs1065852 NC_000022.10:g.42526694G=, NC_000022.10:g.42526694G>A, NC_000022.11:g.42130692G=, NC_000022.11:g.42130692G>A, NG_008376.3:g.4300C=, NG_008376.3:g.4300C>T, NM_000106.5:c.100C=, NM_000106.5:c.100C>T, NM_001025161.2:c.100C=, NM_001025161.2:c.100C>T, NP_000097.3:p.Pro34=, NP_000097.3:p.Pro34Ser, NP_001020332.2:p.Pro34=, NP_001020332.2:p.Pro34Ser, NT_187682.1:g.53033G=, NT_187682.1:g.53033G>A, NW_004504305.1:g.53019A=, NW_004504305.1:g.53019A>G, NW_009646208.1:g.16258A=, NW_009646208.1:g.16258A>G, XM_005278353.1:c.100T=, XM_005278353.1:c.100T>C, XM_005278354.1:c.-1454C>T, XM_005278354.1:c.-1454T>C, XM_005278354.3:c.-1454C>T, XM_005278354.3:c.-1454T>C, XM_011529966.1:c.100C=, XM_011529966.1:c.100C>T, XM_011529967.1:c.100C=, XM_011529967.1:c.100C>T, XM_011529968.1:c.100C=, XM_011529968.1:c.100C>T, XM_011529969.1:c.37+605C>T, XM_011529969.1:c.37+605T>C, XM_011529970.1:c.100C=, XM_011529970.1:c.100C>T, XM_011529971.1:c.37+605C>T, XM_011529971.1:c.37+605T>C, XM_011529972.1:c.100C=, XM_011529972.1:c.100C>T, XM_011547541.1:c.-1454C>T, XM_011547541.1:c.-1454T>C, XM_011547750.1:c.37+605C>T, XM_011547750.1:c.37+605T>C, XM_011547751.1:c.-1114C>T, XM_011547751.1:c.-1114T>C, XM_011547756.1:c.42+469A>G, XM_011547756.1:c.42+469G>A, XM_011548819.1:c.-1454C>T, XM_011548819.1:c.-1454T>C, XP_005278410.1:p.Ser34=, XP_005278410.1:p.Ser34Pro, XP_011528268.1:p.Pro34=, XP_011528268.1:p.Pro34Ser, XP_011528269.1:p.Pro34=, XP_011528269.1:p.Pro34Ser, XP_011528270.1:p.Pro34=, XP_011528270.1:p.Pro34Ser, XP_011528272.1:p.Pro34=, XP_011528272.1:p.Pro34Ser, XP_011528274.1:p.Pro34=, XP_011528274.1:p.Pro34Ser, XR_430455.2:n.328+4A>G, XR_430455.2:n.328+4G>A, XR_952536.1:n.-1751A>G, XR_952536.1:n.-1751G>A, XR_952537.1:n.-1751A>G, XR_952537.1:n.-1751G>A, XR_952538.1:n.-1751A>G, XR_952538.1:n.-1751G>A, XR_952539.1:n.-1462A>G, XR_952539.1:n.-1462G>A, XR_952745.1:n.1257C=, XR_952745.1:n.1257C>T, rs117813846, rs58862176
G > A
SNP
P34S
No VIP available CA VA
rs1080985 NC_000022.10:g.42528382C=, NC_000022.10:g.42528382C>G, NC_000022.11:g.42132375G=, NC_000022.11:g.42132375G>C, NG_008376.3:g.2617C=, NG_008376.3:g.2617C>G, NM_000106.5:c.-1584C>G, NM_000106.5:c.-1584G>C, NM_001025161.2:c.-1584C>G, NM_001025161.2:c.-1584G>C, NT_187682.1:g.54721C=, NT_187682.1:g.54721C>G, NW_004504305.1:g.54705G=, NW_004504305.1:g.54705G>C, NW_009646208.1:g.17943G=, NW_009646208.1:g.17943G>C, XM_005278353.1:c.-1587C>G, XM_005278353.1:c.-1587G>C, XM_011529966.1:c.-1584C>G, XM_011529966.1:c.-1584G>C, XM_011529967.1:c.-1045-539C>G, XM_011529967.1:c.-1045-539G>C, XM_011529968.1:c.-1584C>G, XM_011529968.1:c.-1584G>C, XM_011529969.1:c.-1042C>G, XM_011529969.1:c.-1042G>C, XM_011529970.1:c.-1584C>G, XM_011529970.1:c.-1584G>C, XM_011529971.1:c.-1042C>G, XM_011529971.1:c.-1042G>C, XM_011529972.1:c.-1584C>G, XM_011529972.1:c.-1584G>C, XM_011547750.1:c.-1047C>G, XM_011547750.1:c.-1047G>C, XM_011547756.1:c.42+2157C>G, XM_011547756.1:c.42+2157G>C, XR_430455.2:n.650C>G, XR_430455.2:n.650G>C, XR_952536.1:n.-65C>G, XR_952536.1:n.-65G>C, XR_952537.1:n.-65C>G, XR_952537.1:n.-65G>C, XR_952538.1:n.-65C>G, XR_952538.1:n.-65G>C, XR_952539.1:n.40+185C>G, XR_952539.1:n.40+185G>C, XR_952540.1:n.-1399C>G, XR_952540.1:n.-1399G>C, XR_952745.1:n.-432C>G, XR_952745.1:n.-432G>C, rs61604987
C > G
SNP
VIP No Clinical Annotations available No Variant Annotations available
rs16947 NC_000022.10:g.42523943A=, NC_000022.10:g.42523943A>G, NC_000022.11:g.42127941G=, NC_000022.11:g.42127941G>A, NG_008376.3:g.7051C=, NG_008376.3:g.7051C>T, NM_000106.5:c.886C=, NM_000106.5:c.886C>T, NM_001025161.2:c.733C=, NM_001025161.2:c.733C>T, NP_000097.3:p.Arg296=, NP_000097.3:p.Arg296Cys, NP_001020332.2:p.Arg245=, NP_001020332.2:p.Arg245Cys, NT_187682.1:g.50282A=, NT_187682.1:g.50282A>G, NW_004504305.1:g.50268G=, NW_004504305.1:g.50268G>A, NW_009646208.1:g.13507G=, NW_009646208.1:g.13507G>A, XM_005278353.1:c.742C=, XM_005278353.1:c.742C>T, XM_005278354.1:c.586C=, XM_005278354.1:c.586C>T, XM_005278354.3:c.586C=, XM_005278354.3:c.586C>T, XM_011529966.1:c.886C=, XM_011529966.1:c.886C>T, XM_011529967.1:c.886C=, XM_011529967.1:c.886C>T, XM_011529968.1:c.886C=, XM_011529968.1:c.886C>T, XM_011529969.1:c.742C=, XM_011529969.1:c.742C>T, XM_011529970.1:c.733C=, XM_011529970.1:c.733C>T, XM_011529971.1:c.742C=, XM_011529971.1:c.742C>T, XM_011529972.1:c.843+233C>T, XM_011529972.1:c.843+233T>C, XM_011547541.1:c.586C=, XM_011547541.1:c.586C>T, XM_011547750.1:c.742T=, XM_011547750.1:c.742T>C, XM_011547751.1:c.670T=, XM_011547751.1:c.670T>C, XM_011547756.1:c.-2094A>G, XM_011547756.1:c.-2094G>A, XM_011548819.1:c.586C=, XM_011548819.1:c.586C>T, XP_005278410.1:p.Arg248=, XP_005278410.1:p.Arg248Cys, XP_005278411.1:p.Arg196=, XP_005278411.1:p.Arg196Cys, XP_011528268.1:p.Arg296=, XP_011528268.1:p.Arg296Cys, XP_011528269.1:p.Arg296=, XP_011528269.1:p.Arg296Cys, XP_011528270.1:p.Arg296=, XP_011528270.1:p.Arg296Cys, XP_011528271.1:p.Arg248=, XP_011528271.1:p.Arg248Cys, XP_011528272.1:p.Arg245=, XP_011528272.1:p.Arg245Cys, XP_011528273.1:p.Arg248=, XP_011528273.1:p.Arg248Cys, XP_011545843.1:p.Arg196=, XP_011545843.1:p.Arg196Cys, XP_011546052.1:p.Cys248=, XP_011546052.1:p.Cys248Arg, XP_011546053.1:p.Cys224=, XP_011546053.1:p.Cys224Arg, XP_011547121.1:p.Arg196=, XP_011547121.1:p.Arg196Cys, XR_430455.2:n.-1930A>G, XR_430455.2:n.-1930G>A, XR_952745.1:n.2000+233C>T, XR_952745.1:n.2000+233T>C, rs117039205, rs57836231
A > A
SNP
R296C
VIP No Clinical Annotations available No Variant Annotations available
rs28371706 NC_000022.10:g.42525772G>A, NC_000022.11:g.42129770G>A, NG_008376.3:g.5222C>T, NM_000106.5:c.320C>T, NM_001025161.2:c.320C>T, NP_000097.3:p.Thr107Ile, NP_001020332.2:p.Thr107Ile, NT_187682.1:g.52111G>A, NW_004504305.1:g.52097G>A, NW_009646208.1:g.15336G>A, XM_005278353.1:c.320C>T, XM_005278354.1:c.-532C>T, XM_005278354.3:c.-532C>T, XM_011529966.1:c.320C>T, XM_011529967.1:c.320C>T, XM_011529968.1:c.320C>T, XM_011529969.1:c.177C>T, XM_011529970.1:c.320C>T, XM_011529971.1:c.177C>T, XM_011529972.1:c.320C>T, XM_011547541.1:c.-532C>T, XM_011547750.1:c.177C>T, XM_011547751.1:c.-192C>T, XM_011547756.1:c.-265G>A, XM_011548819.1:c.-532C>T, XP_005278410.1:p.Thr107Ile, XP_011528268.1:p.Thr107Ile, XP_011528269.1:p.Thr107Ile, XP_011528270.1:p.Thr107Ile, XP_011528271.1:p.His59=, XP_011528272.1:p.Thr107Ile, XP_011528273.1:p.His59=, XP_011528274.1:p.Thr107Ile, XP_011546052.1:p.His59=, XR_430455.2:n.-101G>A, XR_952745.1:n.1477C>T, rs587777915, rs59604033
G > A
SNP
T107I
VIP No Clinical Annotations available No Variant Annotations available
rs28371725 NC_000022.10:g.42523805C>T, NC_000022.11:g.42127803C>T, NG_008376.3:g.7189G>A, NM_000106.5:c.985+39G>A, NM_001025161.2:c.832+39G>A, NT_187682.1:g.50144C>T, NW_004504305.1:g.50130C>T, NW_009646208.1:g.13369C>T, XM_005278353.1:c.841+39G>A, XM_005278354.1:c.685+39G>A, XM_005278354.3:c.685+39G>A, XM_011529966.1:c.985+39G>A, XM_011529967.1:c.985+39G>A, XM_011529968.1:c.985+39G>A, XM_011529969.1:c.841+39G>A, XM_011529970.1:c.832+39G>A, XM_011529971.1:c.841+39G>A, XM_011529972.1:c.844-169G>A, XM_011547541.1:c.724G>A, XM_011547750.1:c.841+39G>A, XM_011547751.1:c.769+39G>A, XM_011548819.1:c.724G>A, XP_011545843.1:p.Glu242Lys, XP_011547121.1:p.Glu242Lys, XR_952745.1:n.2001-169G>A, rs57124011, rs587777916
C > T
SNP
VIP No Clinical Annotations available No Variant Annotations available
rs35742686 NC_000022.10:g.42524244delT, NC_000022.11:g.42128242delT, NG_008376.3:g.6750delA, NM_000106.5:c.775delA, NM_001025161.2:c.622delA, NP_000097.3:p.Arg259Glyfs, NP_001020332.2:p.Arg208Glyfs, NT_187682.1:g.50583delT, NW_004504305.1:g.50569delT, NW_009646208.1:g.13808delT, XM_005278353.1:c.631delA, XM_005278354.1:c.475delA, XM_005278354.3:c.475delA, XM_011529966.1:c.775delA, XM_011529967.1:c.775delA, XM_011529968.1:c.775delA, XM_011529969.1:c.631delA, XM_011529970.1:c.622delA, XM_011529971.1:c.631delA, XM_011529972.1:c.775delA, XM_011547541.1:c.475delA, XM_011547750.1:c.631delA, XM_011547751.1:c.559delA, XM_011547756.1:c.-1793delT, XM_011548819.1:c.475delA, XP_005278410.1:p.Arg211Glyfs, XP_005278411.1:p.Arg159Glyfs, XP_011528268.1:p.Arg259Glyfs, XP_011528269.1:p.Arg259Glyfs, XP_011528270.1:p.Arg259Glyfs, XP_011528271.1:p.Arg211Glyfs, XP_011528272.1:p.Arg208Glyfs, XP_011528273.1:p.Arg211Glyfs, XP_011528274.1:p.Arg259Glyfs, XP_011545843.1:p.Arg159Glyfs, XP_011546052.1:p.Arg211Glyfs, XP_011546053.1:p.Arg187Glyfs, XP_011547121.1:p.Arg159Glyfs, XR_430455.2:n.-1629delT, XR_952745.1:n.1932delA, rs45593132, rs60790764
T > -
T > T
indel
R259G
VIP No Clinical Annotations available No Variant Annotations available
rs3892097 NC_000022.10:g.42524947C=, NC_000022.10:g.42524947C>T, NC_000022.11:g.42128945C=, NC_000022.11:g.42128945C>T, NG_008376.3:g.6047G=, NG_008376.3:g.6047G>A, NM_000106.5:c.506-1A>G, NM_000106.5:c.506-1G>A, NM_001025161.2:c.353-1A>G, NM_001025161.2:c.353-1G>A, NT_187682.1:g.51286C=, NT_187682.1:g.51286C>T, NW_004504305.1:g.51272T=, NW_004504305.1:g.51272T>C, NW_009646208.1:g.14511C=, NW_009646208.1:g.14511C>T, XM_005278353.1:c.363-2A>G, XM_005278353.1:c.363-2G>A, XM_005278354.1:c.207-2A>G, XM_005278354.1:c.207-2G>A, XM_005278354.3:c.207-2A>G, XM_005278354.3:c.207-2G>A, XM_011529966.1:c.506-1A>G, XM_011529966.1:c.506-1G>A, XM_011529967.1:c.506-1A>G, XM_011529967.1:c.506-1G>A, XM_011529968.1:c.506-1A>G, XM_011529968.1:c.506-1G>A, XM_011529969.1:c.363-2A>G, XM_011529969.1:c.363-2G>A, XM_011529970.1:c.353-1A>G, XM_011529970.1:c.353-1G>A, XM_011529971.1:c.363-2A>G, XM_011529971.1:c.363-2G>A, XM_011529972.1:c.506-1A>G, XM_011529972.1:c.506-1G>A, XM_011547541.1:c.207-2A>G, XM_011547541.1:c.207-2G>A, XM_011547750.1:c.363-2A>G, XM_011547750.1:c.363-2G>A, XM_011547751.1:c.290-1A>G, XM_011547751.1:c.290-1G>A, XM_011547756.1:c.-1090C>T, XM_011547756.1:c.-1090T>C, XM_011548819.1:c.207-2A>G, XM_011548819.1:c.207-2G>A, XR_430455.2:n.-926C>T, XR_430455.2:n.-926T>C, XR_952745.1:n.1663-1A>G, XR_952745.1:n.1663-1G>A, rs1800716, rs28371711, rs60082401, rs606231227
C > T
SNP
VIP No Clinical Annotations available No Variant Annotations available
rs5030655 NC_000022.10:g.42525086delA, NC_000022.11:g.42129084delA, NG_008376.3:g.5908delT, NM_000106.5:c.454delT, NM_001025161.2:c.353-140delT, NP_000097.3:p.Trp152Glyfs, NT_187682.1:g.51425delA, NW_004504305.1:g.51411delA, NW_009646208.1:g.14650delA, XM_005278353.1:c.363-141delT, XM_005278354.1:c.155delT, XM_005278354.3:c.155delT, XM_011529966.1:c.454delT, XM_011529967.1:c.454delT, XM_011529968.1:c.454delT, XM_011529969.1:c.311delT, XM_011529970.1:c.353-140delT, XM_011529971.1:c.311delT, XM_011529972.1:c.454delT, XM_011547541.1:c.155delT, XM_011547750.1:c.311delT, XM_011547751.1:c.238delT, XM_011547756.1:c.-951delA, XM_011548819.1:c.155delT, XP_005278411.1:p.Val52Glyfs, XP_011528268.1:p.Trp152Glyfs, XP_011528269.1:p.Trp152Glyfs, XP_011528270.1:p.Trp152Glyfs, XP_011528271.1:p.Val104Glyfs, XP_011528273.1:p.Val104Glyfs, XP_011528274.1:p.Trp152Glyfs, XP_011545843.1:p.Val52Glyfs, XP_011546052.1:p.Val104Glyfs, XP_011546053.1:p.Trp80Glyfs, XP_011547121.1:p.Val52Glyfs, XR_430455.2:n.-787delA, XR_952745.1:n.1611delT, rs11568727, rs28371709
A > -
A > A
indel
W152G
VIP No Clinical Annotations available No Variant Annotations available
rs5030656 NC_000022.10:g.42524176_42524178delCTT, NC_000022.11:g.42128174_42128176delCTT, NG_008376.3:g.6816_6818delAAG, NM_000106.5:c.841_843delAAG, NM_001025161.2:c.688_690delAAG, NP_000097.3:p.Lys281del, NP_001020332.2:p.Lys230del, NT_187682.1:g.50515_50517delCTT, NW_004504305.1:g.50501_50503delCTT, NW_009646208.1:g.13740_13742delCTT, XM_005278353.1:c.697_699delAAG, XM_005278354.1:c.541_543delAAG, XM_005278354.3:c.541_543delAAG, XM_011529966.1:c.841_843delAAG, XM_011529967.1:c.841_843delAAG, XM_011529968.1:c.841_843delAAG, XM_011529969.1:c.697_699delAAG, XM_011529970.1:c.688_690delAAG, XM_011529971.1:c.697_699delAAG, XM_011529972.1:c.841_843delAAG, XM_011547541.1:c.541_543delAAG, XM_011547750.1:c.697_699delAAG, XM_011547751.1:c.625_627delAAG, XM_011547756.1:c.-1861_-1859del, XM_011548819.1:c.541_543delAAG, XP_005278410.1:p.Lys233del, XP_005278411.1:p.Lys181del, XP_011528268.1:p.Lys281del, XP_011528269.1:p.Lys281del, XP_011528270.1:p.Lys281del, XP_011528271.1:p.Lys233del, XP_011528272.1:p.Lys230del, XP_011528273.1:p.Lys233del, XP_011528274.1:p.Lys281del, XP_011545843.1:p.Lys181del, XP_011546052.1:p.Lys233del, XP_011546053.1:p.Lys209del, XP_011547121.1:p.Lys181del, XR_430455.2:n.-1697_-1695del, XR_952745.1:n.1998_2000delAAG, rs587777919
CTT > -
CTT > CTT
indel
VIP No Clinical Annotations available No Variant Annotations available
rs59421388 NC_000022.10:g.42523610C>T, NC_000022.11:g.42127608C>T, NG_008376.3:g.7384G>A, NM_000106.5:c.1012G>A, NM_001025161.2:c.859G>A, NP_000097.3:p.Val338Met, NP_001020332.2:p.Val287Met, NT_187682.1:g.49949C>T, NW_004504305.1:g.49935C>T, NW_009646208.1:g.13174C>T, XM_005278353.1:c.868G>A, XM_005278354.1:c.712G>A, XM_005278354.3:c.712G>A, XM_011529966.1:c.1012G>A, XM_011529967.1:c.1012G>A, XM_011529968.1:c.1012G>A, XM_011529969.1:c.868G>A, XM_011529970.1:c.859G>A, XM_011529971.1:c.868G>A, XM_011529972.1:c.870G>A, XM_011547541.1:c.*118G>A, XM_011547750.1:c.868G>A, XM_011547751.1:c.796G>A, XM_011548819.1:c.*118G>A, XP_005278410.1:p.Val290Met, XP_005278411.1:p.Val238Met, XP_011528268.1:p.Val338Met, XP_011528269.1:p.Val338Met, XP_011528270.1:p.Val338Met, XP_011528271.1:p.Val290Met, XP_011528272.1:p.Val287Met, XP_011528273.1:p.Val290Met, XP_011528274.1:p.Thr290=, XP_011546052.1:p.Val290Met, XP_011546053.1:p.Val266Met, XR_952745.1:n.2027G>A
C > T
SNP
V338M
VIP No Clinical Annotations available No Variant Annotations available
rs61736512 NC_000022.10:g.42525134C>T, NC_000022.11:g.42129132C>T, NG_008376.3:g.5860G>A, NM_000106.5:c.406G>A, NM_001025161.2:c.353-188G>A, NP_000097.3:p.Val136Met, NT_187682.1:g.51473C>T, NW_004504305.1:g.51459C>T, NW_009646208.1:g.14698C>T, XM_005278353.1:c.363-189G>A, XM_005278354.1:c.107G>A, XM_005278354.3:c.107G>A, XM_011529966.1:c.406G>A, XM_011529967.1:c.406G>A, XM_011529968.1:c.406G>A, XM_011529969.1:c.263G>A, XM_011529970.1:c.353-188G>A, XM_011529971.1:c.263G>A, XM_011529972.1:c.406G>A, XM_011547541.1:c.107G>A, XM_011547750.1:c.263G>A, XM_011547751.1:c.190G>A, XM_011547756.1:c.-903C>T, XM_011548819.1:c.107G>A, XP_005278411.1:p.Arg36His, XP_011528268.1:p.Val136Met, XP_011528269.1:p.Val136Met, XP_011528270.1:p.Val136Met, XP_011528271.1:p.Arg88His, XP_011528273.1:p.Arg88His, XP_011528274.1:p.Val136Met, XP_011545843.1:p.Arg36His, XP_011546052.1:p.Arg88His, XP_011546053.1:p.Val64Ile, XP_011547121.1:p.Arg36His, XR_430455.2:n.-739C>T, XR_952745.1:n.1563G>A
C > T
SNP
V136M
No VIP available CA VA
rs762551 NC_000015.10:g.74749576C>A, NC_000015.9:g.75041917C>A, NG_008431.1:g.32035C>A, NM_000761.3:c.-9-154C>A, NM_000761.4:c.-9-154C>A, rs17861151, rs57172993
C > A
SNP
Alleles, Functions, and Amino Acid Translations are all sourced from dbSNP 147

Overview

Generic Names
  • Thioridazin
  • Thioridazine Chloride
  • Thioridazine Hcl
  • Thioridazine Hydrochloride
  • Thoridazine Hydrochloride
Trade Names
  • Aldazine
  • Mallorol
  • Malloryl
  • Meleril
  • Mellaril
  • Mellaril Hydrochloride
  • Mellaril-S
  • Mellarit
  • Mellerets
  • Mellerette
  • Melleretten
  • Melleril
  • Metlaril
  • Novoridazine
  • Orsanil
  • Ridazin
  • Ridazine
  • Sonapax
  • Sonapax Hydrochloride
  • Stalleril
  • Thioridazine Hcl Intensol
  • Thioridazine, Prolongatum
  • Tioridazin
Brand Mixture Names

PharmGKB Accession Id

PA451666

Type(s):

Drug

Description

A phenothiazine antipsychotic used in the management of psychoses, including schizophrenia, and in the control of severely disturbed or agitated behavior. It has little antiemetic activity. Thioridazine has a higher incidence of antimuscarinic effects, but a lower incidence of extrapyramidal symptoms, than chlorpromazine. (From Martindale, The Extra Pharmacopoeia, 30th ed, p618)

Source: Drug Bank

Indication

For the treatment of schizophrenia and generalized anxiety disorder.

Source: Drug Bank

Other Vocabularies

Information pulled from DrugBank has not been reviewed by PharmGKB.

Pharmacology, Interactions, and Contraindications

Mechanism of Action

Thioridazine blocks postsynaptic mesolimbic dopaminergic D1 and D2 receptors in the brain; blocks alpha-adrenergic effect, depresses the release of hypothalamic and hypophyseal hormones and is believed to depress the reticular activating system thus affecting basal metabolism, body temperature, wakefulness, vasomotor tone, and emesis.

Source: Drug Bank

Pharmacology

Thioridazine is a trifluoro-methyl phenothiazine derivative intended for the management of schizophrenia and other psychotic disorders. Thioridazine has not been shown effective in the management of behaviorial complications in patients with mental retardation.

Source: Drug Bank

Absorption, Distribution, Metabolism, Elimination & Toxicity

Biotransformation

Hepatic

Source: Drug Bank

Protein Binding

95%

Source: Drug Bank

Absorption

60%

Source: Drug Bank

Half-Life

21-25 hours

Source: Drug Bank

Toxicity

LD 50=956-1034 mg/kg (Orally in rats); Agitation, blurred vision, coma, confusion, constipation, difficulty breathing, dilated or constricted pupils, diminished flow of urine, dry mouth, dry skin, excessively high or low body temperature, extremely low blood pressure, fluid in the lungs, heart abnormalities, inability to urinate, intestinal blockage, nasal congestion, restlessness, sedation, seizures, shock

Source: Drug Bank

Chemical Properties

Chemical Formula

C21H26N2S2

Source: Drug Bank

Isomeric SMILES

CN1CCCCC1CCN2c3ccccc3Sc4c2cc(cc4)SC

Source: OpenEye

Canonical SMILES

CSC1=CC2=C(SC3=CC=CC=C3N2CCC2CCCCN2C)C=C1

Source: Drug Bank

Average Molecular Weight

370.575

Source: Drug Bank

Monoisotopic Molecular Weight

370.153740222

Source: Drug Bank

SMILES

CSC1=CC2=C(SC3=CC=CC=C3N2CCC2CCCCN2C)C=C1

Source: Drug Bank

InChI String

InChI=1S/C21H26N2S2/c1-22-13-6-5-7-16(22)12-14-23-18-8-3-4-9-20(18)25-21-11-10-17(24-2)15-19(21)23/h3-4,8-11,15-16H,5-7,12-14H2,1-2H3

Source: Drug Bank

PharmGKB Curated Pathways

Pathways created internally by PharmGKB based primarily on literature evidence.

  1. Antiarrhythmic Pathway, Pharmacodynamics
    Pharmacodynamic pathway of antiarrhythmic drugs in a stylized cardiac myocyte.

External Pathways

Links to non-PharmGKB pathways.

PharmGKB contains no links to external pathways for this drug. To report a pathway, click here.

Genes that are associated with this drug in PharmGKB's database based on (1) variant annotations, (2) literature review, (3) pathways or (4) information automatically retrieved from DrugBank, depending on the "evidence" and "source" listed below.

Curated Information ?

Drug Targets

Gene Description
ADRA1A (source: Drug Bank)
ADRA1B (source: Drug Bank)
DRD1 (source: Drug Bank)
DRD2 (source: Drug Bank)
HTR2A (source: Drug Bank)
KCNH2 (source: Drug Bank)

Drug Interactions

Interaction Description
amiodarone - thioridazine Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank)
amiodarone - thioridazine Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank)
amitriptyline - thioridazine Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank)
amitriptyline - thioridazine Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank)
astemizole - thioridazine Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank)
astemizole - thioridazine Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank)
atomoxetine - thioridazine The CYP2D6 inhibitor could increase the effect and toxicity of atomoxetine (source: Drug Bank)
bromocriptine - thioridazine The phenothiazine decreases the effect of bromocriptine (source: Drug Bank)
bromocriptine - thioridazine The phenothiazine decreases the effect of bromocriptine (source: Drug Bank)
bupropion - thioridazine Inceases the effect and toxicity of thioridazine (source: Drug Bank)
bupropion - thioridazine Inceases the effect and toxicity of thioridazine (source: Drug Bank)
chloroquine - thioridazine Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank)
chloroquine - thioridazine Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank)
chlorpromazine - thioridazine Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank)
chlorpromazine - thioridazine Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank)
cisapride - thioridazine Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank)
cisapride - thioridazine Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank)
dexfenfluramine - thioridazine Decreased anorexic effect, may increase psychotic symptoms (source: Drug Bank)
diethylpropion - thioridazine Decreased anorexic effect, may increase psychotic symptoms (source: Drug Bank)
diltiazem - thioridazine Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank)
diltiazem - thioridazine Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank)
diphenhydramine - thioridazine Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank)
diphenhydramine - thioridazine Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank)
disopyramide - thioridazine Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank)
disopyramide - thioridazine Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank)
donepezil - thioridazine Possible antagonism of action (source: Drug Bank)
donepezil - thioridazine Possible antagonism of action (source: Drug Bank)
doxepin - thioridazine Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank)
doxepin - thioridazine Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank)
duloxetine - thioridazine Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank)
duloxetine - thioridazine Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank)
erythromycin - thioridazine Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank)
erythromycin - thioridazine Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank)
fenfluramine - thioridazine Decreased anorexic effect, may increase psychotic symptoms (source: Drug Bank)
fenfluramine - thioridazine Decreased anorexic effect, may increase psychotic symptoms (source: Drug Bank)
flecainide - thioridazine Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank)
flecainide - thioridazine Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank)
fluoxetine - thioridazine Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank)
fluoxetine - thioridazine Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank)
galantamine - thioridazine Possible antagonism of action (source: Drug Bank)
galantamine - thioridazine Possible antagonism of action (source: Drug Bank)
gatifloxacin - thioridazine Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank)
gatifloxacin - thioridazine Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank)
grepafloxacin - thioridazine Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank)
grepafloxacin - thioridazine Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank)
guanethidine - thioridazine The agent decreases the effect of guanethidine (source: Drug Bank)
guanethidine - thioridazine Thioridazine may decrease the effect of guanethidine. (source: Drug Bank)
halofantrine - thioridazine Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank)
halofantrine - thioridazine Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank)
haloperidol - thioridazine Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank)
haloperidol - thioridazine Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank)
imipramine - thioridazine Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank)
imipramine - thioridazine Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank)
levofloxacin - thioridazine Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank)
levofloxacin - thioridazine Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank)
maprotiline - thioridazine Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank)
maprotiline - thioridazine Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank)
mazindol - thioridazine Decreased anorexic effect, may increase psychotic symptoms (source: Drug Bank)
mazindol - thioridazine Decreased anorexic effect, may increase psychotic symptoms (source: Drug Bank)
pentamidine - thioridazine Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank)
pentamidine - thioridazine Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank)
phentermine - thioridazine Decreased anorexic effect, may increase psychotic symptoms (source: Drug Bank)
phenylpropanolamine - thioridazine Decreased anorexic effect, may increase psychotic symptoms (source: Drug Bank)
pimozide - thioridazine Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank)
pimozide - thioridazine Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank)
pindolol - thioridazine Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank)
pindolol - thioridazine Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank)
procainamide - thioridazine Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank)
procainamide - thioridazine Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank)
propafenone - thioridazine Increased risk of cardiotoxicity and arrhytmias (source: Drug Bank)
propafenone - thioridazine Increased risk of cardiotoxicity and arrhytmias (source: Drug Bank)
propranolol - thioridazine Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank)
propranolol - thioridazine Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank)
quinidine - thioridazine Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank)
quinidine - thioridazine Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank)
quinine - thioridazine Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank)
quinine - thioridazine Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank)
ranolazine - thioridazine Possible additive effect on QT prolongation (source: Drug Bank)
tacrine - thioridazine The therapeutic effects of the central acetylcholinesterase inhibitor (ACEI), Tacrine, and/or the anticholinergic/antipsychotic, Thioridazine, may be reduced due to antagonism. This interaction may be beneficial when the anticholinergic action is a side effect. ACEIs may also augment the central neurotoxic effect of antipsychotics. Monitor for extrapyramidal symptoms and decreased efficacy of both agents. (source: Drug Bank)
tacrine - thioridazine The therapeutic effects of the central acetylcholinesterase inhibitor (AChEI), Tacrine, and/or the anticholinergic/antipsychotic, Thioridazine, may be reduced due to antagonism. This interaction may be beneficial when the anticholinergic action is a side effect. AChEIs may also augment the central neurotoxic effect of antipsychotics. Monitor for extrapyramidal symptoms and decreased efficacy of both agents. (source: Drug Bank)
tamoxifen - thioridazine Thioridazine may decrease the therapeutic effect of Tamoxifen by decreasing the production of active metabolites. Consider alternate therapy. (source: Drug Bank)
tamoxifen - thioridazine Thioridazine may decrease the therapeutic effect of Tamoxifen by decreasing the production of active metabolites. Consider alternate therapy. (source: Drug Bank)
tamsulosin - thioridazine Thioridazine, a CYP2D6 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP2D6 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Thioridazine is initiated, discontinued, or dose changed. (source: Drug Bank)
tamsulosin - thioridazine Thioridazine, a CYP2D6 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP2D6 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Thioridazine is initiated, discontinued, or dose changed. (source: Drug Bank)
telithromycin - thioridazine Telithromycin may increase the QTc-prolonging effect of Thioridazine. Concomitant therapy should be avoided. (source: Drug Bank)
terfenadine - thioridazine Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank)
terfenadine - thioridazine Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank)
tetrabenazine - thioridazine May cause dopamine deficiency. Monitor for Tetrabenazine adverse effects. (source: Drug Bank)
thioridazine - amiodarone Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank)
thioridazine - amiodarone Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank)
thioridazine - amitriptyline Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank)
thioridazine - amitriptyline Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank)
thioridazine - amphetamine Decreased anorexic effect, may increase psychotic symptoms (source: Drug Bank)
thioridazine - amphetamine Decreased anorexic effect, may increase psychotic symptoms (source: Drug Bank)
thioridazine - astemizole Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank)
thioridazine - astemizole Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank)
thioridazine - atomoxetine The CYP2D6 inhibitor could increase the effect and toxicity of atomoxetine (source: Drug Bank)
thioridazine - atomoxetine The CYP2D6 inhibitor could increase the effect and toxicity of atomoxetine (source: Drug Bank)
thioridazine - benzphetamine Decreased anorexic effect, may increase psychotic symptoms (source: Drug Bank)
thioridazine - benzphetamine Decreased anorexic effect, may increase psychotic symptoms (source: Drug Bank)
thioridazine - bretylium Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank)
thioridazine - bretylium Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank)
thioridazine - bromocriptine The phenothiazine decreases the effect of bromocriptine (source: Drug Bank)
thioridazine - bromocriptine The phenothiazine decreases the effect of bromocriptine (source: Drug Bank)
thioridazine - bupropion Bupropion increases the effect and toxicity of thioridazine (source: Drug Bank)
thioridazine - bupropion Bupropion increases the effect and toxicity of thioridazine (source: Drug Bank)
thioridazine - chloroquine Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank)
thioridazine - chloroquine Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank)
thioridazine - chlorpromazine Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank)
thioridazine - chlorpromazine Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank)
thioridazine - cisapride Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank)
thioridazine - cisapride Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank)
thioridazine - dexfenfluramine Decreased anorexic effect, may increase psychotic symptoms (source: Drug Bank)
thioridazine - dexfenfluramine Decreased anorexic effect, may increase psychotic symptoms (source: Drug Bank)
thioridazine - dextroamphetamine Decreased anorexic effect, may increase psychotic symptoms (source: Drug Bank)
thioridazine - dextroamphetamine Decreased anorexic effect, may increase psychotic symptoms (source: Drug Bank)
thioridazine - diethylpropion Decreased anorexic effect, may increase psychotic symptoms (source: Drug Bank)
thioridazine - diethylpropion Decreased anorexic effect, may increase psychotic symptoms (source: Drug Bank)
thioridazine - diltiazem Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank)
thioridazine - diltiazem Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank)
thioridazine - diphenhydramine Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank)
thioridazine - diphenhydramine Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank)
thioridazine - disopyramide Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank)
thioridazine - disopyramide Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank)
thioridazine - dofetilide Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank)
thioridazine - dofetilide Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank)
thioridazine - donepezil Possible antagonism of action (source: Drug Bank)
thioridazine - donepezil Possible antagonism of action (source: Drug Bank)
thioridazine - doxepin Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank)
thioridazine - doxepin Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank)
thioridazine - duloxetine Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank)
thioridazine - duloxetine Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank)
thioridazine - erythromycin Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank)
thioridazine - erythromycin Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank)
thioridazine - fenfluramine Decreased anorexic effect, may increase psychotic symptoms (source: Drug Bank)
thioridazine - fenfluramine Decreased anorexic effect, may increase psychotic symptoms (source: Drug Bank)
thioridazine - flecainide Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank)
thioridazine - flecainide Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank)
thioridazine - fluoxetine Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank)
thioridazine - fluoxetine Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank)
thioridazine - fluvoxamine Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank)
thioridazine - fluvoxamine Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank)
thioridazine - galantamine Possible antagonism of action (source: Drug Bank)
thioridazine - galantamine Possible antagonism of action (source: Drug Bank)
thioridazine - gatifloxacin Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank)
thioridazine - gatifloxacin Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank)
thioridazine - grepafloxacin Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank)
thioridazine - grepafloxacin Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank)
thioridazine - guanethidine The agent decreases the effect of guanethidine (source: Drug Bank)
thioridazine - guanethidine Thioridazine may decrease the effect of guanethidine. (source: Drug Bank)
thioridazine - halofantrine Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank)
thioridazine - halofantrine Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank)
thioridazine - haloperidol Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank)
thioridazine - haloperidol Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank)
thioridazine - imipramine Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank)
thioridazine - imipramine Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank)
thioridazine - josamycin Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank)
thioridazine - josamycin Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank)
thioridazine - levofloxacin Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank)
thioridazine - levofloxacin Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank)
thioridazine - maprotiline Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank)
thioridazine - maprotiline Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank)
thioridazine - mazindol Decreased anorexic effect, may increase psychotic symptoms (source: Drug Bank)
thioridazine - mazindol Decreased anorexic effect, may increase psychotic symptoms (source: Drug Bank)
thioridazine - methamphetamine Decreased anorexic effect, may increase psychotic symptoms (source: Drug Bank)
thioridazine - methamphetamine Decreased anorexic effect, may increase psychotic symptoms (source: Drug Bank)
thioridazine - metrizamide Increased risk of convulsions (source: Drug Bank)
thioridazine - metrizamide Increased risk of convulsions (source: Drug Bank)
thioridazine - paroxetine Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank)
thioridazine - paroxetine Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank)
thioridazine - penicillin g Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank)
thioridazine - penicillin g Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank)
thioridazine - pentamidine Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank)
thioridazine - pentamidine Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank)
thioridazine - phendimetrazine Decreased anorexic effect, may increase psychotic symptoms (source: Drug Bank)
thioridazine - phendimetrazine Decreased anorexic effect, may increase psychotic symptoms (source: Drug Bank)
thioridazine - phenmetrazine Decreased anorexic effect, may increase psychotic symptoms (source: Drug Bank)
thioridazine - phenmetrazine Decreased anorexic effect, may increase psychotic symptoms (source: Drug Bank)
thioridazine - phentermine Decreased anorexic effect, may increase psychotic symptoms (source: Drug Bank)
thioridazine - phentermine Decreased anorexic effect, may increase psychotic symptoms (source: Drug Bank)
thioridazine - phenylpropanolamine Decreased anorexic effect, may increase psychotic symptoms (source: Drug Bank)
thioridazine - phenylpropanolamine Decreased anorexic effect, may increase psychotic symptoms (source: Drug Bank)
thioridazine - pimozide Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank)
thioridazine - pimozide Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank)
thioridazine - pindolol Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank)
thioridazine - pindolol Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank)
thioridazine - procainamide Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank)
thioridazine - procainamide Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank)
thioridazine - propafenone Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank)
thioridazine - propafenone Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank)
thioridazine - propranolol Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank)
thioridazine - propranolol Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank)
thioridazine - quinidine Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank)
thioridazine - quinidine Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank)
thioridazine - quinidine Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank)
thioridazine - quinine Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank)
thioridazine - quinine Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank)
thioridazine - ranolazine Possible additive effect on QT prolongation (source: Drug Bank)
thioridazine - ranolazine Possible additive effect on QT prolongation (source: Drug Bank)
thioridazine - rivastigmine Possible antagonism of action (source: Drug Bank)
thioridazine - rivastigmine Possible antagonism of action (source: Drug Bank)
thioridazine - sertindole Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank)
thioridazine - sertindole Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank)
thioridazine - sotalol Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank)
thioridazine - sotalol Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank)
thioridazine - sparfloxacin Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank)
thioridazine - sparfloxacin Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank)
thioridazine - terfenadine Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank)
thioridazine - terfenadine Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank)
thioridazine - ziprasidone Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank)
thioridazine - ziprasidone Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank)
thiothixene - thioridazine May cause additive QTc-prolonging effects. Concomitant therapy is contraindicated. (source: Drug Bank)
thiothixene - thioridazine May cause additive QTc-prolonging effects. Concomitant therapy is contraindicated. (source: Drug Bank)
ticlopidine - thioridazine Ticlopidine may decrease the metabolism of Thioridazine. Concomitant therapy is contraindicated. (source: Drug Bank)
toremifene - thioridazine May cause additive QTc-prolonging effects. Concomitant therapy is contraindicated. (source: Drug Bank)
tramadol - thioridazine Thioridazine may decrease the effect of Tramadol by decreasing active metabolite production. (source: Drug Bank)
tranylcypromine - thioridazine Tranylcypromine, a CYP2D6 inhibitor, may decrease the metabolism and clearance of Thioridazine. Concomitant therapy is contraindicated. (source: Drug Bank)
trazodone - thioridazine The 2D6 inhibitor, Trazodone, may increase the efficacy of Thioridazine by decreasing Thioridazine metabolism and clearance. Monitor for changes in Thioridazine efficacy if Trazodone is initiated, discontinued or dose changed. (source: Drug Bank)
trazodone - thioridazine The 2D6 inhibitor, Trazodone, may increase the efficacy of Thioridazine by decreasing Thioridazine metabolism and clearance. Monitor for changes in Thioridazine efficacy if Trazodone is initiated, discontinued or dose changed. (source: Drug Bank)
trimethobenzamide - thioridazine Trimethobenzamide and Thioridazine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects. (source: Drug Bank)
trimipramine - thioridazine May cause additive QTc-prolonging effects. Concomitant therapy is contraindicated. (source: Drug Bank)
triprolidine - thioridazine The antihistamine, Triprolidine, may increase the arrhythmogenic effect of the phenothiazine, Thioridazine. Monitor for symptoms of ventricular arrhythmias. Additive anticholinergic and CNS depressant effects may also occur. Monitor for enhanced anticholinergic and CNS depressant effects. (source: Drug Bank)
triprolidine - thioridazine The antihistamine, Triprolidine, may increase the arrhythmogenic effect of the phenothiazine, Thioridazine. Monitor for symptoms of ventricular arrhythmias. Additive anticholinergic and CNS depressant effects may also occur. Monitor for enhanced anticholinergic and CNS depressant effects. (source: Drug Bank)
trospium - thioridazine Trospium and Thioridazine, two anticholinergics, may cause additive anticholinergic effects and enhanced adverse/toxic effects. Monitor for enhanced anticholinergic effects. (source: Drug Bank)
voriconazole - thioridazine Additive QTc prolongation may occur. Concomitant use is contraindicated. (source: Drug Bank)
vorinostat - thioridazine Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP). (source: Drug Bank)
ziprasidone - thioridazine Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy is contraindicated. (source: Drug Bank)
zuclopenthixol - thioridazine Additive QTc-prolonging effects increases risk of cardiac arrhythmias. Concomitant therapy is contraindicated. (source: Drug Bank)

Curated Information ?

Relationships from National Drug File - Reference Terminology (NDF-RT)

May Treat
Contraindicated With

Publications related to thioridazine: 19

No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Challenges in pharmacogenetics. European journal of clinical pharmacology. 2013. Cascorbi Ingolf, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
KCNH2 pharmacogenomics summary. Pharmacogenetics and genomics. 2010. Oshiro Connie, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Drug-induced long QT syndrome. Pharmacological reviews. 2010. Kannankeril Prince, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Systematic review of pharmacoeconomic studies of pharmacogenomic tests. Pharmacogenomics. 2010. Beaulieu Mathieu, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Drug- and non-drug-associated QT interval prolongation. British journal of clinical pharmacology. 2010. van Noord Charlotte, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Coprescription of tamoxifen and medications that inhibit CYP2D6. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2010. Sideras Kostandinos, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Cytochrome P450 2D6. Pharmacogenetics and genomics. 2009. Owen Ryan P, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Relevance of CYP2D6 -1584C>G polymorphism for thioridazine:mesoridazine plasma concentration ratio in psychiatric patients. Pharmacogenomics. 2009. Dorado Pedro, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Comparison of the effects of thioridazine and mesoridazine on the QT interval in healthy adults after single oral doses. Clinical pharmacology and therapeutics. 2007. Salih I S M, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Factors affecting drug concentrations and QT interval during thioridazine therapy. Clinical pharmacology and therapeutics. 2007. Thanacoody R H K, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Comparative metabolic capabilities and inhibitory profiles of CYP2D6.1, CYP2D6.10, and CYP2D6.17. Drug metabolism and disposition: the biological fate of chemicals. 2007. Shen Hongwu, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Functional polymorphisms of the cytochrome P450 1A2 (CYP1A2) gene and prolonged QTc interval in schizophrenia. Progress in neuro-psychopharmacology & biological psychiatry. 2007. Tay Joshua K X, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Risk of extrapyramidal syndrome in schizophrenic patients treated with antipsychotics: a population-based study. Clinical pharmacology and therapeutics. 2007. Yang S-Y, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
The phenothiazine drugs inhibit hERG potassium channels. Drug and chemical toxicology. 2005. Kim Ki-Suk, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
A comparison of the receptor binding and HERG channel affinities for a series of antipsychotic drugs. European journal of pharmacology. 2002. Kongsamut Sathapana, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Science, medicine, and the future: Pharmacogenetics. BMJ (Clinical research ed.). 2000. Wolf C R, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Inhibition of human hepatic cytochrome P4502E1 by azole antifungals, CNS-active drugs and non-steroidal anti-inflammatory agents. Xenobiotica; the fate of foreign compounds in biological systems. 1998. Tassaneeyakul W, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Selective serotonin reuptake inhibitors and CNS drug interactions. A critical review of the evidence. Clinical pharmacokinetics. 1997. Sproule B A, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Plasma levels of thioridazine and metabolites are influenced by the debrisoquin hydroxylation phenotype. Clinical pharmacology and therapeutics. 1991. von Bahr C, et al. PubMed

LinkOuts

Web Resource:
Wikipedia
National Drug Code Directory:
0378-0612-01
DrugBank:
DB00679
ChEBI:
9566
KEGG Drug:
D00373
PubChem Compound:
5452
PubChem Substance:
148555
46509070
IUPHAR Ligand:
100
Drugs Product Database (DPD):
360244
ChemSpider:
5253
Therapeutic Targets Database:
DAP000476
FDA Drug Label at DailyMed:
56b3f4c2-52af-4947-b225-6808ae9f26f5

Clinical Trials

These are trials that mention thioridazine and are related to either pharmacogenetics or pharmacogenomics.

No trials found.

Common Searches

Search PubMed
Search Medline Plus
Search PubChem
Search CTD

Sources for PharmGKB drug information: DrugBank, PubChem.